title: Autophagy in tumour cell death.
abstract: In every moment of a cell's existence one key question is always asked, "To be or not to be"? Cells constantly weigh up signals from their environment against their own integrity and metabolic status and decide whether to live or die. Such cell death decisions are central to the progression and treatment of cancer. The term autophagy describes three processes that deliver cytoplasmic macromolecules and organelles to lysosomes for degradation, the difference between each form being the method of delivery. The most extensively studied form is macroautophagy (hereafter referred to as autophagy) where cytosolic components are engulfed by double membraned autophagosomes. Autophagosomes fuse with lysosomes to form structures called autolysosomes, within which organelles, proteins and other macromolecules are degraded by catabolic enzymes in the acidic lysosome environment. Autophagy, which normally occurs at low levels in unstressed cells, is widely regarded as having a positive effect on cell health as potentially harmful protein aggregates and damaged organelles can be recycled. During periods of nutrient shortage autophagy is enhanced to provide, albeit temporarily, an internal energy source. Autophagy is also enhanced by other stresses encountered by tumour cells and this may protect the cell or aid its demise. In this review we examine the effect of autophagy on cell death decisions in tumour cells.
authors.affiliation: Cancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK.
authors.forename: Robin L
authors.initials: RL
authors.lastname: Macintosh
authors.forename: Kevin M
authors.initials: KM
authors.lastname: Ryan
mesh_terms: D000818:Animals; D001343:Autophagy / Q000502:physiology*; D006801:Humans; D008247:Lysosomes / Q000502:physiology; D009369:Neoplasms / Q000473:pathology*
keywords: Apoptosis; Autophagy; CML; CQ; CTL; Cancer; Cell death; DAMP; ECM; HDACi; MOMP; PDAC; RCC; ROS; SAHA; TKi; chloroquine; chronic myeloid leukaemia; cytotoxic T-lymphocyte; danger-associated molecular pattern; extracellular matrix; histone deacetylase inhibitor; mitochondrial outer membrane permiabilisation; pancreatic ductal adenocarcinoma; reactive oxygen species; renal cell carcinoma; suberoylanilide hydroxamic acid; tyrosine kinase inhibitor